Victoria Aguilera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/713803/publications.pdf

Version: 2024-02-01

88 2,358 24
papers citations h-index

97 97 97 2329 all docs docs citations times ranked citing authors

206102

48

g-index

#	Article	IF	Citations
1	Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal of Hepatology, 2016, 65, 524-531.	3.7	298
2	Clinical Benefits of Antiviral Therapy in Patients with Recurrent Hepatitis C Following Liver Transplantation. American Journal of Transplantation, 2008, 8, 679-687.	4.7	269
3	Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. Journal of Hepatology, 2006, 44, 717-722.	3.7	170
4	Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplantation, 2006, 12, 1067-1076.	2.4	154
5	Are posttransplantation protocol liver biopsies useful in the long term?. Liver Transplantation, 2001, 7, 790-796.	2.4	122
6	Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transplantation, 2008, 14, 1449-1460.	2.4	101
7	Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transplantation, 2006, 12, 762-767.	2.4	81
8	Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: Impact of donor age and baseline cirrhosis. Liver Transplantation, 2009, 15, 738-746.	2.4	65
9	Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transplantation, 2005, 11, 456-462.	2.4	63
10	Effect of Calcineurin Inhibitors in the Outcome of Liver Transplantation in Hepatitis C Virus-Positive Recipients. Transplantation, 2010, 90, 1204-1209.	1.0	62
11	Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. Liver Transplantation, 2009, 15, 79-87.	2.4	60
12	Liver transplantation and hepatitisÂC. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 805-812.	1.5	59
13	Long-term outcome of â€~long-term liver transplant survivors'. Transplant International, 2013, 26, 740-750.	1.6	53
14	Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?. Liver Transplantation, 2002, 8, 1020-1027.	2.4	47
15	Delayed onset of severe hepatitis C-related liver damage following liver transplantation: A matter of concern?. Liver Transplantation, 2003, 9, 1152-1158.	2.4	47
16	Comparison of two non-contemporaneous HCV-liver transplant cohorts: Strategies to improve the efficacy of antiviral therapy. Journal of Hepatology, 2012, 56, 1310-1316.	3.7	42
17	Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. Liver Transplantation, 2015, 21, 812-822.	2.4	39
18	Chronic Kidney Disease After Liver Transplantation. Transplantation, 2013, 95, 1148-1153.	1.0	35

#	Article	IF	CITATIONS
19	Cyclosporine A-Based Immunosuppression Reduces Relapse Rate After Antiviral Therapy in Transplanted Patients With Hepatitis C Virus Infection: A Large Multicenter Cohort Study. Transplantation, 2011, 92, 334-340.	1.0	34
20	Performance of the OraQuick Hepatitis C virus antibody test in oral fluid and fingerstick blood before and after treatment-induced viral clearance. Journal of Clinical Virology, 2018, 102, 77-83.	3.1	33
21	227 LONG-TERM RESULTS WITH THE USE OF GRAFTS FROM HBSAG NEGATIVE HBCAB POSITIVE DONORS IN LIVER TRANSPLANTATION. Journal of Hepatology, 2008, 48, S93.	3.7	32
22	Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. American Journal of Transplantation, 2018, 18, 2513-2522.	4.7	32
23	Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transplantation, 2014, 20, 25-34.	2.4	31
24	Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. Hepatology, 2016, 63, 488-498.	7.3	27
25	Automated Whole-Liver MRI Segmentation to Assess Steatosis and Iron Quantification in Chronic Liver Disease. Radiology, 2022, 302, 345-354.	7.3	25
26	Control of Blood Pressure in Liver Transplant Recipients. Transplantation, 2012, 93, 1031-1037.	1.0	21
27	Hepatobiliary and Pancreatic: A fatal case of extensive splanchnic vein thrombosis in a patient with Covidâ€19. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1853-1853.	2.8	21
28	Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. Liver Transplantation, 2009, 15, 1798-1807.	2.4	20
29	Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study. Journal of Hepatology, 2015, 62, 92-100.	3.7	20
30	Impact of hepatitis C virus (<scp>HCV</scp>) antiviral treatment on the need for liver transplantation (<scp>LT</scp>). Liver International, 2018, 38, 1022-1027.	3.9	20
31	Digital pathology: accurate technique for quantitative assessment of histological features in metabolicâ€associated fatty liver disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 160-171.	3.7	20
32	Disease Reversibility in Patients With Post-Hepatitis C Cirrhosis. Transplantation, 2017, 101, 916-923.	1.0	19
33	Fat and liver transplantation: clinical implications. Transplant International, 2018, 31, 828-837.	1.6	19
34	Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: Role of an aggressive approach. Liver Transplantation, 2013, 19, 69-77.	2.4	18
35	Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis. Annals of Hepatology, 2019, 18, 855-861.	1.5	17
36	Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin. Liver Transplantation, 2011, 17, 1318-1327.	2.4	13

#	Article	IF	CITATIONS
37	Indications for and Results of Liver Retransplantation. Transplantation Proceedings, 2009, 41, 1016-1017.	0.6	12
38	Comparison of results of combined liver-kidney transplantation vs. isolated liver transplantation. Annals of Hepatology, 2013, 12, 274-281.	1.5	12
39	Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. World Journal of Gastroenterology, 2016, 22, 4547.	3.3	12
40	Cirrosis por hepatitis C. Estado actual. Medicina ClÃnica, 2017, 148, 78-85.	0.6	11
41	Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir. Annals of Hepatology, 2013, 12, 974-978.	1.5	9
42	Association of Cardiac Abnormalities to the Frail Phenotype in Cirrhotic Patients on the Waitlist. Transplantation, 2018, 102, e101-e107.	1.0	9
43	Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes. Journal of Clinical Virology, 2012, 53, 231-238.	3.1	7
44	Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study. Transplant International, 2018, 31, 649-657.	1.6	7
45	Digital Pathology Enables Automated and Quantitative Assessment of Inflammatory Activity in Patients with Chronic Liver Disease. Biomolecules, 2021, 11, 1808.	4.0	6
46	Hepatitis C-related cirrhosis. Current status. Medicina ClÃnica (English Edition), 2017, 148, 78-85.	0.2	4
47	Biomechanical analysis of expert anesthesiologists and novice residents performing a simulated central venous access procedure. PLoS ONE, 2021, 16, e0250941.	2.5	4
48	Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation. Cellular Immunology, 2022, 371, 104455.	3.0	4
49	Human immunodeficiency virus–infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study. Liver Transplantation, 2017, 23, 645-651.	2.4	3
50	Hepatitis C and fibrosis. Revista Espanola De Enfermedades Digestivas, 2004, 96, 402-8; 409-14.	0.3	3
51	94 CALCINEURIN INHIBITORS AND OUTCOME OF LIVER TRANSPLANTATION IN HCV-POSITIVE RECIPIENTS: FINAL RESULTS OF A PROSPECTIVE RANDOMIZED STUDY. Journal of Hepatology, 2010, 52, S43.	3.7	2
52	Pilot validation study of a rapid test in oral fluid for population screening of hepatitis C virus infection. Journal of Hepatology, 2017, 66, S403-S404.	3.7	2
53	Peritransplant Antiviral Treatment of Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients. Liver Transplantation, 2018, 24, 1476-1480.	2.4	2
54	Periesophageal Lymph Node Metastasis of Prostate Adenocarcinoma From Liver Transplant Donor. American Journal of Gastroenterology, 2019, 114, 378-378.	0.4	2

#	Article	IF	Citations
55	Metabolic syndrome before liver transplantation: does it have an impact on post liver transplantation outcomes?. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.3	2
56	Comparison of results of combined liver-kidney transplantation vs. isolated liver transplantation. Annals of Hepatology, 2013, 12, 274-81.	1.5	2
57	Sinusoidal obstruction syndrome after liver transplantation: A multicenter observational study. Liver Transplantation, 2022, 28, 1257-1261.	2.4	2
58	Inadequate social support decreases survival in decompensated liver cirrhosis patients. GastroenterologÃa Y HepatologÃa, 2023, 46, 28-38.	0.5	2
59	[137] RESPONSE TO PEGYLATED INTERFERON-RIBAVIRIN IN PATIENTS WITH RECURRENT HEPATITIS C IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR MIXED (ALCOHOL-HCV) CIRRHOSIS. Journal of Hepatology, 2007, 46, S62.	3.7	1
60	Protocolo diagn?stico y tratamiento del paciente con trasplante hep?tico reciente y alteraci?n de las pruebas de funci?n hep?tica. Medicine, 2008, 10, 817-820.	0.0	1
61	Indications and results of liver retransplantation: experience with 1181 patients in the hospital universitario La Fe. CirugÃa Española (English Edition), 2010, 87, 356-363.	0.1	1
62	451 NO IMPACT OF OBESITY ON POST-LIVER TRANSPLANTATION OUTCOME AMONG HCV-INFECTED LIVER TRANSPLANT RECIPIENTS. Journal of Hepatology, 2010, 52, S183.	3.7	1
63	P1207 TRIPLE THERAPY FOR HCV CIRRHOSIS IN LIVER TRANSPLANT CANDIDATES. HIGH RATE OF PREVENTION OF HCV RECURRENCE AFTER LIVER TRANSPLANTATION (LT) IN WELL SELECTED PATIENTS. Journal of Hepatology, 2014, 60, S490.	3.7	1
64	Efficacy and Clinical Impact of Daclatasvir-Based Antiviral Therapy in Severe Recurrent Hepatitis C after Liver Transplantation. Results from a Multicenter Spanish Group. Journal of Hepatology, 2016, 64, S547.	3.7	1
65	Alarming decrease in patient survival among HCV-infected liver transplant recipients. Journal of Hepatology, 2001, 34, 32-33.	3.7	1
66	Hepatocellular carcinoma (HCC): Can it still be considered acontroversial indication for liver transplantation (LT)?. Journal of Hepatology, 2000, 32, 53.	3.7	0
67	Recurrence of Hepatitis C After Liver Transplantation. Transplantation Proceedings, 2005, 37, 3311-3312.	0.6	0
68	127 Liver transplantation for HCV-alcohol aetiology: Is the outcome similar to those to HCV or alcohol alone?. Journal of Hepatology, 2006, 44, S56-S57.	3.7	0
69	450 LOW EFFICACY OF ANTIVIRAL THERAPY IN HCV-LIVER TRANSPLANT RECIPIENTS TREATED AT ADVANCED STAGES OF FIBROSIS. Journal of Hepatology, 2010, 52, S183.	3.7	0
70	490 IMPACT OF OBESITY ON SURVIVAL IN PATIENTS UNDERGOING LIVER TRANSPLANTATION. Journal of Hepatology, 2010, 52, S198.	3.7	0
71	517 POST-LIVER TRANSPLANTATION (LT) OUTCOME IN HIV/HCV CO-INFECTED PATIENTS. COMPARISON WITH MONOINFECTED PATIENTS WITH HCV-CIRRHOSIS. Journal of Hepatology, 2011, 54, S212.	3.7	0
72	521 PATIENTS SURVIVING AT LEAST 10 YEARS POST LIVER TRANSPLANTATION: LONG TERM COMPLICATIONS. Journal of Hepatology, 2011, 54, S213-S214.	3.7	0

#	Article	IF	CITATIONS
73	540 VALIDATION OF A PREDICTIVE MODEL FOR CHRONIC RENAL DYSFUNCTION FOLLOWING LIVER TRANSPLANTATION. Journal of Hepatology, 2011, 54, S221.	3.7	0
74	806 TRIPHASIC VIRAL LOAD KINETICS OF HEPATITIS C VIRUS DURING ANTIVIRAL THERAPY POST-TRANSPLANTATION: EFFECT OF THE TYPE OF PEGYLATED-IFN AND BASELINE IMMUNOSUPPRESSION. Journal of Hepatology, 2011, 54, S323-S324.	3.7	O
75	195 LONG-TERM OUTCOME OF LIVER TRANSPLANTATION FOR HEPATITIS B WITH ANTI-HBC POSITIVE GRAFTS. Journal of Hepatology, 2012, 56, S83-S84.	3.7	0
76	915 WORSE TOLERABILITY OF TRIPLE THERAPY IN SPECIAL POPULATIONS: CIRRHOTICS AND LIVER TRANSPLANT RECIPIENTS. Journal of Hepatology, 2013, 58, S377.	3.7	0
77	1225 TOLERABILITY TO ANTIVIRAL DUAL AND TRIPLE THERAPY IN LIVER TRANSPLANT RECIPIENTS. Journal of Hepatology, 2013, 58, S497.	3.7	O
78	Hepatitis C Virus Recurrence After Liver Transplantation: How to Treat and When. Transplantation Proceedings, 2014, 46, 3100-3103.	0.6	0
79	P903 CONTROL OF DIABETES MELLITUS (DM) IN LIVER TRANSPLANT RECIPIENTS (LTR). Journal of Hepatology, 2014, 60, S375-S376.	3.7	O
80	P910 IMPACT OF ANEMIA IN VIRAL RESPONSE DURING TRIPLE THERAPY IN LIVER TRANSPLANT RECIPIENTS. Journal of Hepatology, 2014, 60, S378.	3.7	0
81	P1143 APPLICABILITY OF TRIPLE THERAPY IN CIRRHOTIC POPULATION: VALIDATION OF CUPIC DATA. Journal of Hepatology, 2014, 60, S463.	3.7	O
82	P894 PROPHYLAXIS OF DE NOVO HEPATITIS B VIRUS INFECTION WITH LAMIVUDINE IN HBsAg-NEGATIVE NAIVE RECIPIENTS OF HEPATITIS B CORE ANTIBODY-POSITIVE LIVERS: A 13-YEAR SINGLE-CENTER EXPERIENCE. Journal of Hepatology, 2014, 60, S372.	3.7	0
83	Peri-Transplant Treatment with Direct-Acting Antivirals of HIV-HCV Coinfected Patients. Journal of Hepatology, 2016, 64, S552.	3.7	O
84	Corrigendum to "Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study―[J Hepatol 2015;62:92–100]. Journal of Hepatology, 2016, 64, 757.	3.7	0
85	Interferon-free therapy is effective and safe for hepatitis C recurrence in liver transplant hepatitis C virus/human immunodeficiency virus coinfected recipients: a case-control study. Journal of Hepatology, 2017, 66, S189.	3.7	O
86	Cardiovascular risk and liver transplantation in HIV patients. Are HIV infected liver transplant recipients at higher risk?. Journal of Liver Transplantation, 2021, 1, 100005.	0.4	0
87	Rechazo cr $ ilde{A}^3$ nico. , 2008, , 303-310.		O
88	Anemia hemolÃtica por anticuerpos del sistema ABO o Rh en pacientes receptores de trasplante de órgano sólido. Medicina ClÃnica, 2003, 120, 177-179.	0.6	0